Early Pregnancy Markers to Predict Gestational Diabetes and Large Baby Risk Using Skin Autofluorescence and Glycated Albumin Compared to HbA1c

What this Trial Is About

Gestational diabetes mellitus GDM during pregnancy increases the risk of having a large baby macrosomia and other complications for both mother and child. This trial is designed to compare new markers of sugar damage in the body, such as skin autofluorescence and glycated albumin, with the traditional HbA1c test. Researchers want to see how well these markers predict GDM, macrosomia, and related pregnancy outcomes in women before 28 weeks of pregnancy. Pregnant women under 28 weeks of gestation, with or without risk factors for GDM, will be enrolled during their first consultation at the maternity hospital. The study will measure glycation markers including HbA1c, glycated albumin, and skin autofluorescence to assess their potential as early predictors. This is an interventional diagnostic study without placebo or masking. Participants will be monitored mainly during the first trimester for the development of GDM. The study will also track various maternal, fetal, and neonatal health outcomes from delivery day to the following day. The primary outcome is the incidence of GDM diagnosed during pregnancy. Safety and health of mother and baby will be evaluated closely around the time of delivery. The trial is expected to continue through September 2028.

New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.